BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

NCT01938846 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: BI 860585
DRUG: exemestane
DRUG: BI 860585
DRUG: BI 860585
DRUG: paclitaxel

Sponsor

Boehringer Ingelheim